Best Alternatives to Mirador Therapeutics

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment.

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and e

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research a

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a pro

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — t

Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clini

Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (

Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andr

ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body w

Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contr

Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in Mar

eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes tha

PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic ef

Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to